AbbVie Gross Margin 2010-2023 | ABBV

Current and historical gross margin for AbbVie (ABBV) over the last 10 years. The current gross profit margin for AbbVie as of December 31, 2023 is %.
AbbVie Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2023-12-31 $54.32B $33.90B 62.42%
2023-09-30 $55.14B $36.26B 65.76%
2023-06-30 $56.02B $38.61B 68.91%
2023-03-31 $56.74B $39.39B 69.43%
2022-12-31 $58.05B $40.64B 70.00%
2022-09-30 $57.82B $40.26B 69.62%
2022-06-30 $57.35B $40.42B 70.48%
2022-03-31 $56.73B $39.44B 69.53%
2021-12-31 $56.20B $38.75B 68.96%
2021-09-30 $55.17B $37.36B 67.72%
2021-06-30 $53.73B $35.26B 65.62%
2021-03-31 $50.20B $32.54B 64.82%
2020-12-31 $45.80B $30.42B 66.41%
2020-09-30 $40.65B $27.94B 68.74%
2020-06-30 $36.23B $26.65B 73.56%
2020-03-31 $34.06B $26.37B 77.43%
2019-12-31 $33.27B $25.83B 77.64%
2019-09-30 $32.87B $25.41B 77.32%
2019-06-30 $32.62B $25.25B 77.41%
2019-03-31 $32.65B $25.16B 77.07%
2018-12-31 $32.75B $25.04B 76.44%
2018-09-30 $32.19B $24.21B 75.22%
2018-06-30 $30.95B $23.19B 74.93%
2018-03-31 $29.61B $22.26B 75.17%
2017-12-31 $28.22B $21.17B 75.04%
2017-09-30 $27.27B $20.96B 76.85%
2017-06-30 $26.71B $20.51B 76.78%
2017-03-31 $26.22B $20.14B 76.81%
2016-12-31 $25.64B $19.81B 77.25%
2016-09-30 $25.24B $19.49B 77.21%
2016-06-30 $24.75B $19.34B 78.12%
2016-03-31 $23.78B $18.85B 79.28%
2015-12-31 $22.86B $18.36B 80.31%
2015-09-30 $21.91B $17.77B 81.09%
2015-06-30 $20.99B $16.92B 80.60%
2015-03-31 $20.44B $16.17B 79.12%
2014-12-31 $19.96B $15.53B 77.83%
2014-09-30 $19.62B $15.03B 76.61%
2014-06-30 $19.26B $14.67B 76.18%
2014-03-31 $19.02B $14.50B 76.20%
2013-12-31 $18.79B $14.21B 75.62%
2013-09-30 $18.89B $14.32B 75.83%
2013-06-30 $18.74B $14.25B 76.06%
2013-03-31 $18.54B $14.03B 75.70%
2012-12-31 $18.38B $13.87B 75.47%
2012-09-30 $18.04B $11.36B 62.99%
2012-06-30 $17.94B $12.28B 68.44%
2012-03-31 $17.72B $13.13B 74.11%
2011-12-31 $17.44B $12.80B 73.40%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $300.196B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77